Oncogenic role of SND1 in development and progression of hepatocellular carcinoma

57Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

SND1, a subunit of the miRNA regulatory complex RISC, has been implicated as an oncogene in hepatocellular carcinoma (HCC). In this study, we show that hepatocyte-specific SND1 transgenic mice (Alb/SND1 mice) develop spontaneous HCC with partial penetrance and exhibit more highly aggressive HCC induced by chemical carcinogenesis. Livers from Alb/SND1 mice exhibited a relative increase in inflammatory markers and spheroid-generating tumor-initiating cells (TIC). Mechanistic investigations defined roles for Akt and NF-κB signaling pathways in promoting TIC formation in Alb/SND1 mice. In human xenograft models of subcutaneous or orthotopic HCC, administration of the selective SND1 inhibitor 3′, 5′-deoxythymidine bisphosphate (pdTp), inhibited tumor formation without effects on body weight or liver function. Our work establishes an oncogenic role for SND1 in promoting TIC formation and highlights pdTp as a highly selective SND1 inhibitor as a candidate therapeutic lead to treat advanced HCC.

Cite

CITATION STYLE

APA

Jariwala, N., Rajasekaran, D., Mendoza, R. G., Shen, X. N., Siddiq, A., Akiel, M. A., … Sarkar, D. (2017). Oncogenic role of SND1 in development and progression of hepatocellular carcinoma. Cancer Research, 77(12), 3306–3316. https://doi.org/10.1158/0008-5472.CAN-17-0298

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free